Naveed Shams - Santen Pharmaceutical CEO
SNPHY Stock | USD 9.75 0.07 0.72% |
CEO
Naveed Shams is Chief Scientific Officer, Executive Officer and Presidentident and CEO of Subsidiary of Santen Pharmaceutical Co since 2017.
Tenure | 7 years |
Phone | 81 6 7664 8621 |
Web | https://www.santen.com |
Santen Pharmaceutical Management Efficiency
Santen Pharmaceutical's management efficiency ratios could be used to measure how well Santen Pharmaceutical manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
Showing other executives | CEO Age | ||
Richard Saynor | Novartis AG ADR | 57 | |
Bruno Strigini | Novartis AG ADR | N/A | |
Severin Schwan | Roche Holding AG | 56 | |
Osamu Nagayama | Roche Holding AG | 69 | |
Pascal Soriot | AstraZeneca PLC | 58 | |
PerOlof Attinger | Roche Holding | 58 | |
Michael Heuer | Roche Holding AG | 64 | |
Michael Ball | Novartis AG ADR | 62 | |
Jacob Naarden | Eli Lilly And | 39 | |
Francesco Balestrieri | Novartis AG ADR | N/A | |
Pascal Soriot | AstraZeneca PLC ADR | 60 | |
Paul Hudson | Novartis AG ADR | 51 | |
William Anderson | Roche Holding AG | 57 | |
Joseph Jimenez | Novartis AG ADR | 58 | |
Osamu Nagayama | Roche Holding | 69 | |
Michael Heuer | Roche Holding | 64 | |
Chris Ilsley | Novartis AG ADR | N/A | |
PerOlof Attinger | Roche Holding AG | 58 | |
William Anderson | Roche Holding | 57 | |
Severin Schwan | Roche Holding | 56 | |
Elizabeth Barrett | Novartis AG ADR | 56 |
Management Performance
Return On Equity | -0.0264 | |||
Return On Asset | -0.001 |
Santen Pharmaceutical Leadership Team
Elected by the shareholders, the Santen Pharmaceutical's board of directors comprises two types of representatives: Santen Pharmaceutical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Santen. The board's role is to monitor Santen Pharmaceutical's management team and ensure that shareholders' interests are well served. Santen Pharmaceutical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Santen Pharmaceutical's outside directors are responsible for providing unbiased perspectives on the board's policies.
Satoshi Suzuki, Executive Officer, Chief Director of Planning | ||
Kanoko Ohishi, Independent Director | ||
Nikolas Tripodis, Chief Officer | ||
Noriaki Yamamoto, CIO, Head of Information Systems Division and Corporate Officer | ||
Akira Kurokawa, CEO and President Director, Member of Nominating Committee, Member of Executive Compensation Committee and Member of Corporate Strategy Committee | ||
Hidetaka Mizutani, Manager of Finance & Accounting Group | ||
Kenji Morishima, Executive Officer, Chief Director of Human Resources & Organization Development and CSR | ||
Nobuko Kato, Chief Officer | ||
Sadatoshi Furukado, Senior Managing Executive Officer, Director of Medical Business, Director | ||
Ken Araki, Executive Officer, Senior Director of Global Business Development | ||
Mika Masunari, G Officer | ||
Masamichi Sato, Head of CSR and General Affairs Division and Sr. Corporate Officer of Corporate Devel. | ||
Kazuo Koshiji, CFO, Head of Fin. Division and Sr. Corporate Officer | ||
Kaori Itagaki, Gen Group | ||
Akihiro Tsujimura, Executive Officer, Director of Asia Business | ||
Takeshi Ito, Executive Officer, Senior Director of Medicine Sales in Medicine Business Unit | ||
Shinichi Teramachi, Head Officer | ||
Frank Binder, Executive Officer, Chief Director of Supply Chain | ||
Ippei Kurihara, Japan Department | ||
Yutaro Shintaku, Independent Director | ||
Akihiro Okumura, Independent Director | ||
Yutaro Shinta, Independent Director | ||
Jyrki Liljeroos, Executive Officer and Presidentident of Subsidiary | ||
Shiro Hatagami, Manager of Finance & Accounting Group | ||
Keizo Nakada, Executive Officer, Chief Director of Product Supply | ||
Ko Takahashi, Executive Officer | ||
Akio Kimura, Executive Officer, Chief Director of Reliability Guarantee | ||
Miki Fujima, Executive Officer, Chief Director of Human Resources | ||
Naveed Shams, Chief Scientific Officer, Executive Officer and Presidentident and CEO of Subsidiary | ||
Atsutoshi Ohta, Executive Officer, Chief Director of Production & Logistics | ||
Hiroyuki Yamazaki, Executive Officer, Senior Director of Pharmaceutical Sales in Pharmaceutical Business Unit | ||
Takahiro Morita, Executive Officer, Senior Director of Pharmaceutical Sales in Pharmaceutical Business Unit | ||
Ye Liu, Executive Officer, General Manager of Subsidiary | ||
Takayuki Katayama, Independent Director | ||
Luis Iglesias, Executive Officer | ||
Shigeo Taniuchi, Executive Officer and Presidentident of Subsidiary | ||
Kunihito Minakawa, Independent Director | ||
Minori Hara, Chief Officer |
Santen Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Santen Pharmaceutical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | -0.0264 | |||
Return On Asset | -0.001 | |||
Profit Margin | (0.03) % | |||
Operating Margin | (0) % | |||
Current Valuation | 2.6 B | |||
Shares Outstanding | 388.22 M | |||
Shares Owned By Institutions | 0.02 % | |||
Price To Earning | 14.22 X | |||
Price To Book | 1.39 X | |||
Price To Sales | 0.01 X |
Currently Active Assets on Macroaxis
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Santen Pharmaceutical Co. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in rate. Note that the Santen Pharmaceutical information on this page should be used as a complementary analysis to other Santen Pharmaceutical's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.
Complementary Tools for Santen Pink Sheet analysis
When running Santen Pharmaceutical's price analysis, check to measure Santen Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Santen Pharmaceutical is operating at the current time. Most of Santen Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of Santen Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Santen Pharmaceutical's price. Additionally, you may evaluate how the addition of Santen Pharmaceutical to your portfolios can decrease your overall portfolio volatility.
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
Transaction History View history of all your transactions and understand their impact on performance | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance |